US Patent Granted for Verona Pharma’s RPL554
News Jan 01, 2013
Verona Pharma plc has announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554.
The patent is the fourth patent issued for RPL554 and related compounds in the US.
RPL554, Verona Pharma's lead drug candidate, is a dual phosphodiesterase 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties.
RPL554 is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
The Company is currently carrying out clinical trials of the drug to further characterize its bronchodilator and anti-inflammatory effects.
Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We are growing the intellectual property portfolio around the RPL554 programme and the issue of this new US Patent strengthens and harmonizes our international patent estate around RPL554 and provides exclusivity in one of the world’s leading pharmaceutical markets. We continue to develop our intellectual property rights as this is a key part of Verona Pharma’s strategy.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE